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Abstract: In scientific literature, there are many programs that predict linear B-cell epitopes from a protein sequence. Each
program generates multiple B-cell epitopes that can be individually studied. This paper defines a function called <C> that
combines  results  from five different  prediction programs concerning the  linear  B-cell  epitopes (ie.,  BebiPred,  EPMLR,
BCPred, ABCPred and Emini Prediction) for selecting the best B-cell epitopes.  We obtained 17 potential  linear B cells
consensus epitopes from Glycoprotein E from serotype IV of the dengue virus for exploring new possibilities in vaccine
development. The direct implication of the results obtained is to open the way to experimentally validate more epitopes to
increase the efficiency of the available treatments against dengue and to explore the methodology in other diseases.
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1. Introduction
Bioinformatics has contributed to the  in silico design of
vaccines  by  identifying  immunologically  significant
sequences,  using  recently  developed  computational
methodologies  [1-3].  Given  the  exponential  growth  of
biological  information  and  technological  advances  in  the
management of data, it has been suggested that the concept
of bioinformatics and computational biology should undergo
a revision  and  use  more  frequently a  working  hypothesis
containing all the available information [4, 5]. An example
of  this  is  the  design of  a  vaccine that  could be  useful  in
malaria,  based  on  a  poly  (amidoamine)  (PAMAM) eight-
branched dendrimeric  structure  formed by a  set  of  B-cell
epitopes [6].
The present paper focused on selecting the best linear B-
cell  epitopes  obtained  by  BePiPred,  EPMLR,  BCPred,
ABCPred, and Emini prediction programs according to Isea
methodology [2, 3, 5, 6]. This methodology was applied on
the dengue virus serotype that was detected in Venezuela for
exploring  new  possibilities  in  vaccine  development.  It  is
important to consider that any proposed dengue vaccine must
fulfill a series of requirements such as providing a long-term
protection  and  a  heterotypic  protection.  Also,  the  vaccine
must  be  able  to  protect  the  individual  against  the  four
serotypes of dengue virus as well as have a low production
cost.
As explained in [7-10], the first step to predict linear B-
cell epitopes is to identify the protein targets, and in the case
of dengue virus, the glycoprotein E is the first option to find
the  B  epitope.  In  fact,  glycoprotein  E  and  the  C  and  M
proteins were tested in the immunization assays of mice and
were proven to be capable of providing protection against
lethal  doses  of  dengue  virus  [11].  This  article  only
considered the dengue virus E glycoprotein.
The next section will  describe the methodology for  the
quantitative selection of potential linear B-cell epitopes that
are  generated  by  BePiPred,  EPMLR,  BCPred,  ABCPred,
and  Emini  Prediction  programs  with  the  sequences  of
dengue serotype 4 that  currently exists  in  the Venezuelan
outbreak
2. Materials and Methods
First, the protein sequences of the glycoprotein E in the
NCBI  database  have  to  be  identified.  This  paper  only
considers the serotype 4 that was isolated in Venezuela. The
linear  B-cell  epitopes  were  predicted  with BePiPred  [12],
EPMLR  [13],  BCPred  [14],  ABCPred  [15],  and  Emini
Prediction  programs  [16].  Given  that  each  program
generates  a  wide  variety  of  potential  B-cells  epitopes,  a
strategy  was  developed to  select  the  best  set  of  epitopes.
This procedure is as follows:
2 Raul Isea:  Quantitative Prediction of Linear B-Cell Epitopes
a. The  epitopes  that  overlap  in  at  least  three  or  more
regions of the prediction were selected. For example,
the  following  epitopes  were  predicted:
VMKRYSAPSE (region between amino acids 1 until
10), RYSAPSESE (region 4 until 12), YSAPSESEGV
(5 until 14), and YSAPSESEGVL (5 until 15). Then,
the four epitope predictions were aligned to overlap in
the same region as illustrated below:
Position: 1      5       10     15
          VMKRYSAPSE
                  RYSAPSESE
                          YSAPSESEGV           
                YSAPSESEGVL
In order to do this, a script in Python was developed to
overlap all the B-cells epitopes in the target protein and to
select  the  regions  with  three  or  more  coincidences.
According  to  the  above  example,  the  resulting  epitope  is
YSAPSESE which is between the regions 5 and 12. Then,
the regions where there was no consensus of at least three
amino acids as shown in gray, were omitted.
b. Each amino acid was scored according to the frequency
in which it appears in all predictions. This means that
according  to  the  above  example,  valine,  methionine
and  lysine  at  positions  1,  2,  and  3,  respectively  are
equal  to  one.  The  tyrosine  (position  5)  until  the
glutamic acid (position 12) has the frequency 4, and so
on.
c. The epitope obtained that overlap in three amino acids
is YSAPSESE.
d. The value of <C> was determined as the sum of the
frequency of amino acids divided by the total length of
the  predicted  epitope.  In  the  above  example  (i.e.,
YSAPSESE), <C> is (4 + 4 + 4 + 4 + 4 + 4 + 3 + 3)/8
= 3.75.
e. The epitopes whose <C> value is greater than or equal
to 3.5 are selected. This restriction can be reduced to a
value of 3, but it is important to select these epitopes
that have a value greater than <C>.
Finally, these results are compared with the linear B-cell
epitopes  found in the Immune Epitope  Database  Analysis
(IEDB) database [17]. The goal is to see if some of the B-
cell  epitopes  that  have  already  been  used  in  scientific
literature can be reproduced.
3. Results and Discussions
31 sequences of the glycoprotein E of the dengue virus
serotype  4  were  found  in  the  National  Center  for
Biotechnology Information (NCBI) database, whose ID are:
ACH61691,  ACH61692,  ACH99663,  ACH99664,
ACL99023,  ACL99024,  ACL99026,  ACL99031,
ACL99035,  ACO06199,  ACQ44389,  ACQ44390,
ACQ44392,  ACQ44393,  ACQ44395,  ACQ44396,
ACQ44397,  ACQ44398,  ACQ44399,  ACQ44400,
ACQ44401,  ACS32010,  ACW82930,  ACW82931,
ACW82932,  ACW82933,  AEA50926,  AEA50927,
AET43237, AET43240, and AEX09559.
The linear  B-cell  of  each sequence  found in the NCBI
database  was  predicted  using  the  five  programs indicated
before  [7-10].  Each  program  generates  multiple  B-cell
epitopes as shown in the following example. Consider the E
glycoprotein whose ID is ACH61691 (length 3387 aa). The
BepiPred obtained 97 lineal B-cell epitopes whose length is
equal to five or more amino acids (the threshold is 0.35 for
this program). The ABCPred predicted 104 epitopes of the
length of 10 amino acids whose score is equal to or greater
than  0.7  (threshold  is  0.51).  The  EPMLR  obtained  208
epitopes of the length of 9 amino acids whose score is equal
to  or  greater  than  0.7  (threshold  is  -015).  The  program
BCPred based on the flexible prediction method obtained
144 epitopes with a specificity of 75%. The Emili procedure
generated 83 epitopes with a threshold of 1.0 and a window
size of 3. Thus, the sequence ACH61691 yielded 636 linear
B-cell epitopes.
Glycoprotein E from serotype IV of the dengue virus has
31 different  sequences in the NCBI database,  resulting in
more than 1,800 linear epitopes. Using the above-mentioned
methodology  it  was  possible  to  remove  the  epitopes  that
overlap in at  least  three or  more regions in  all  prediction
programs.  After  applying  the  above  procedure  for  all  E
glycoproteins, seventeen epitopes were obtained that have a
value  of  <C>  greater  than  3.6  as  indicated  in  table  1.
According  to  the  results  shown  in  table  1,  only  seven
epitopes have a value of <C> greater than four.
Table 1. Linear B-cell epitopes generated for all glycoprotein E of dengue
serotype 4 present in Venezuela with <C> value equal to or greater than
3.6 (see text for details).
Region Epitope <C>
909-924 IDGPDTSECPNERRAW 4.25
1811-1820 REIPERSWNT 4.20
1983-1992 FGPEREKTQA 4.20
807-817 KFQPESPARLA 4.10
1643-1653 ERIGEPDYEVD 4.10
2056-2066 WTREGEKKKLR 4.10
2040-2047 GERNNQIL 4.00
2848-2856 VDTRTPQPKPG 3.82
1438-1545 RLEPSWADV 3.78
1790-1805 ATPPGATDPFPQSNSP 3.75
2126-2133 TERGGRAY 3.75
3179-3197 IPQWEPSKGWKNWQEVPFC 3.74
2214-2222 EPEKQRTPQ 3.67
196-203 SGERRREK 3.63
1938-1945 NPAQEDDQ 3.63
1556-1568 GWRLGDKWDKEED 3.62
647-655 IELEPPFGDS 3.60
Finally, the entire IEDB database was searched for all the
lineal B-cells epitopes used in the experiments based on the
dengue serotype  4.  The result  is  shown in table  2.  When
comparing  the  two  tables,  it  is  evident  that  there  are
coincidences  between  the  computational  methodology
presented in this paper and that found in IEDB, which are
highlighted in bold type. These coincidences indicate that it
is possible to reduce the number of linear B cells that can be
used in an experiment.
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4. Conclusions
As explained above, one protein sequence can generate
multiple linear B-cell epitopes and for this reason, this paper
proposes  a  computational  methodology  to  reduce  the
number  of  linear  B-cell  epitopes  and  thus  allow  one  to
rationally select those B-cell epitopes that can be predicted
more accurately.
By comparing the results obtained in table 1 with respect
to the epitopes obtained from the scientific literature given
in table 2, it can be seen that there is a correlation between
the two. However, it is necessary to verify these results with
experimental tests that will be conducted in the future. Once
there  is  agreement  between  the  experiment  and  this
methodology, a  web  version  will  be  developed  using  the
python script.
Table  2.  Linear  B-cell  epitopes  obtained  from  the  IEDB  database
corresponding to dengue serotype 4 data.
ID IEDB Epitope
16649 FLIDGPDTSECPNERRA
27016 ILEENMEVEIWTREGEKKKL
30831 KFQPESPARLASAILNA
41821 MKFREGSSEVC
73272 WYGMEIRPLSEKEENMV
145953 PWHLGKLEIDFGECPGTTVTIQEDCDHRGPSLRTTTASGKLVTQWC
145998 SECPNERRAWNFLEVEDYGFGMFTTNIW
151601 ADLSLEKAANVQWDE
179894 RTTTASGKLVT
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